GlassScriptPhysician profile
Varinder Tut
NPI 1467080028
$952.08
in general payments reported to CMS, 2019-2025
18 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $586 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $952.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $279.74 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $182.21 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.95 | 2024-2025 | Jardiance |
| Axsome Therapeutics, INC. | $68.57 | 2024-2025 | Auvelity, Sunosi |
| Exact Sciences Corporation | $52.80 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $34.12 | 2024-2025 | Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $32.43 | 2024-2025 | Arexvy, Trelegy Ellipta |
| Amgen INC. | $21.99 | 2024 | Repatha, Otezla |
| Biotronik INC. | $21.35 | 2024 | Biomonitor |
| Azurity Pharmaceuticals, INC. | $21.24 | 2025 | Horizant |
| Philips North America LLC | $19.97 | 2025 | Home Pi Undivided |
| Mayne Pharma Commercial LLC | $18.61 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $17.66 | 2024 | Airsupra |
| Medtronic, INC. | $17.54 | 2025 | Intellis Adaptivestim |
| Harmony Biosciences LLC | $15.80 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $14.95 | 2024 | Licart, Tirosint |
| Amneal Pharmaceuticals LLC | $14.84 | 2024 | Unithroid |
| Janssen Pharmaceuticals, INC | $14.31 | 2024 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varinder Tut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.